Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 1, 2005, Pages 194-201

  Gokhale, Abhay S ^a   Mayadev, Jyoti ^a   Pohlman, Brad ^a   Macklis, Roger M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Ibritumomab tiuxetan; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

ANTIBODIES; COMPUTERIZED TOMOGRAPHY; DISEASES; IMMUNOLOGY; MEDICAL IMAGING; YTTRIUM;

IBRITUMOMAB TIUXETAN; NON-HODGKIN'S LYMPHOMA; RADIOIMMUNOTHERAPY; TUMOR PROGRESSION;

RADIOTHERAPY;

CD20 ANTIBODY; CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB; DIAGNOSTIC AGENT; INDIUM; MONOCLONAL ANTIBODY; YTTRIUM;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BEAM THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DRUG UPTAKE; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; TUMOR LOCALIZATION; TUMOR VOLUME; EVALUATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DISEASE PROGRESSION; FEMALE; GAMMA CAMERAS; HUMANS; INDIUM RADIOISOTOPES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RADIOIMMUNOTHERAPY; RECURRENCE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 26944501648     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.01.017     Document Type: Article

References (28)

1. Fisher RJ. Overview of non-Hodgkin's lymphoma: Biology, staging, and treatment. Semin Oncol 2003;30(Suppl. 4):3-9.
2. Seymour JF. New treatment approaches to indolent NHL. Semin Oncol 2004;31(Suppl. 2):27-32.
3. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002;20: 3545-3557.
4. Tobinai K. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. Int J Clin Oncol 2003;8:212-223.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphomas: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
6. Zevalin (ibritumomab tiuxetan) prescribing information. Cambridge, MA: Biogen Idee Inc.; 2002.
7. BEXXAR (tositumomab) prescribing information. Seattle, WA: Corixa Corporation; 2003.
8. Cheson BD. Radioimmunotherapy for non-Hodgkin lymphoma. Blood 2003;101:391-398.
9. Kaminisky MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.
10. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B 8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-3803.
11. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-2463.
12. Macklis R, Molina A, Pohlman B, et al. Long-term responses in patients with relapsed or refractory follicular lymphoma treated with yttrium 90 ibritumomab tiuxetan (Zevalin) [Abstract]. Int J Radiat Oncol Biol Phys 2004;60(Suppl. 1):S542.
13. Knox SK, Meredith RF, Coleman M, et al. Tositumomab and iodine I 131 tositumomab (BEXXAR therapeutic regimen) produces long-term durable responses in heavily pretreated patients with relapsed, refractory, and transformed low-grade non-Hodgkin's lymphoma (NHL) [Abstract]. Int J Radiat Oncol Biol Phys 2004;60(Suppl. 1):S220.
14. Hagenbeek A. Radioimmunotherapy for NHL: Experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma 2003;44(Suppl. 4):S37-S47.
15. Czuczman MS, Emmanouilides CE, Witzig T, et al. Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Abstract presented at 38th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL: May 18-21, 2002.
16. Armitage JO, Leonard JP, Gregory SJ, et al. The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/ refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL) [Abstract]. J Clin Oncol 2004; 22(Suppl. 14):6573.
17. Sgouros G, Squeri S, Ballangrud A, et al. Patient-specific, 3 dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131-I-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med 2003;44:260-268.
18. Koral KF, Dewaraja L, Clarke A, et al. Tumor absorbed dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report. Cancer Biother Radiopharm 2000; 15:347-355.
19. Koral KF, Francis IR, Kroll S, et al. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy: Conjugate views compared with a hybrid method. Cancer 2002; 94(Suppl. 4):1258-1263.
20. Montoto S, Lopez-Guillermo A, Altes A, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004;15:1484-1489.
21. Montoto S, Lopez-Guillermo A, Ferrer A, et al. Survival after progression in patients with follicular lymphoma: Analysis of prognostic factors. Ann Oncol 2002;13:523-530.
22. Horning SJ, Weller E, Kim KM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004;22:3032-3038.
23. Kaminski MS, Leornard JP, Zelenetz AD, et al. Bexxar therapy (tositumomab and iodine I 131 tositumomab) has high response rates in the treatment of bulky low grade (LG) relapsed or refractory non-Hodgkin's lymphoma (NHL). Abstract presented at 38th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL: May 18-21, 2002.
24. Kostakoglu L, Leonard JP, Coleman M, et al. Prediction of response to therapy using early F-18 fluorodeoxyglucose imaging (FDG-PET) in patients undergoing I-131 tositumomab therapy. Abstract presented at 37th Annual Meeting of the American Society of Clinical Oncology. San Francisco, CA: May 12-15, 2001.
25. Torizuka T, Zasadny KR, Kison PV, et al. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with PET. J Nucl Med 2000;41:999-1005.
26. Scheidhauer K, Wolf I, Schilling von C, et al. Outcome prediction of radioimmunotherapy of NHL by FDG-PET [Abstract]. Eur J Nucl Med 2002;29(Suppl. 1):S113.
27. Hofmann M, Hertenstein B, Boerner AR, et al. 18-F-FDG-PET in monitoring therapy response to RIT by 131-I Rituximab (Mab-thera) antibody [Abstract]. Ann Oncol 2002;13(Suppl. 2):96.
28. Davies AJ, Rohatiner AZS, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:1469-1479.